Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theragenics (TGX) on the up and up -- Ignore unavailable to you. Want to Upgrade?

To: Mark who wrote (845)	5/11/1998 9:23:00 PM
From: Solid	Respond to of 1055

Has anybody contacted the Co. to know when they will release word to the street about the next cyclo. being up and on line? Or not their style... Solid

To: Mark who wrote (845)	5/11/1998 9:25:00 PM
From: bill hopkins	Read Replies (2) \| Respond to of 1055

THRX ...Post 617 over on the YAHOO thread has some good information in it re conversation with R Warren....http://messages.yahoo.com

To: Mark who wrote (845)	6/2/1998 12:46:00 PM
From: Mark	Respond to of 1055

F.Y.I. ATLANTA--(BW HealthWire)--June 2, 1998--Theragenics Corporation (NASDAQ symbol:THRX), the Atlanta-based cancer treatment producer, today announced the first European TheraSeed(R) implant took place successfully in Milan, Italy on May 27, 1998. The implant was performed by Italian physicians who had attended Indigo Medical, Inc.'s (a Johnson & Johnson Company) first brachytherapy training seminar in Cincinnati in April. The implant was supervised by a leading physician under Indigo's preceptor program. A second TheraSeed implant was performed the following day by the same group of physicians. These implants were performed following the receipt by Theragenics of its CE Mark. The CE marking indicates that TheraSeed meets the health and safety requirements necessary for the product to be freely marketed in the 15 member countries of the European Union. Commenting on these milestones Christine Jacobs, Theragenics' President and CEO said, "Receiving our CE Mark and shipping our first order to Europe is another step forward in the evolution of Theragenics. This is just one example of why the Company's agreement with Indigo is so powerful. It further demonstrates the swiftness with which TheraSeed can now be made available to new markets. I am pleased with the opportunity this accomplishment affords both companies. We look forward to meeting the challenge of supplying both the U.S. and European markets and offering patients everywhere the opportunity to benefit from our exceptional product." Except for historical information contained herein, the matters discussed in this press release, are forward looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Actual results may be affected by, among other things, risks and uncertainties related to new process development cycles, potential costs and delays in capacity expansion, research and development activities, continued acceptance of the product by the market, introduction and/or availability of competitive products by others, third party reimbursement, physician training, and other factors set forth from time to time in the Company's Securities and Exchange Commission filings. Theragenics Corporation, based in Norcross, GA, is the manufacturer of TheraSeed - palladium-103, a rice-sized radioactive device used in the treatment of localized prostate cancer with a one-time, minimally invasive procedure. For additional information on the Company call Theragenics' Investor Relations Department at (800) 998-8479. The Company's common stock is traded on the NASDAQ stock exchange under the symbol THRX. CONTACT: Theragenics Corp., Norcross Ron Warren - Director of Investor Relations phone 800.998.THRX (8479) or 770.381.8338 KEYWORD: GEORGIA INDUSTRY KEYWORD: MEDICINE PRODUCT